RecruitingSecondary Progressive Multiple Sclerosis (SPMS)

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Eligible age

18–65 yrs

Accepts

All genders

Locations

18 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

Sponsor: Novartis Pharmaceuticals

✓ Signed informed consent must be obtained prior to any assessment performed.
✓ Male or female participants aged 18-65 (inclusive) at Screening.
✓ Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018), with current SPMS in accordance with the revised clinical course (Lublin et al 2014) at Screening
✓ Absence of documented clinical relapses in the 24 months before Screening and randomization.
✓ EDSS score of 3.0 to 6.0 (inclusive) at Screening.
✓ Documented evidence of disability progression in the 12 months before Screening.

✕ Unwilling or unable to undergo MRI scans as per protocol (for example, claustrophobia, or presents absolute contraindications to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator)).
✕ History of clinically significant central nervous system (CNS) disease (e.g. stroke, traumatic brain or spinal injury, history or presence of myelopathy) or neurological disorders which may mimic multiple sclerosis (MS).
✕ Ongoing substance abuse (drug or alcohol) or any other factor (e.g. serious psychiatric condition) that may interfere with the participant's ability to cooperate and comply with the study procedures.
✕ Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or neurological symptoms consistent with PML.
✕ Women of childbearing potential (WOCBP), unless they are using highly effective methods of contraception (failure rate \< 1% per year) while taking study treatment and for at least 1 week after stopping study treatment.
✕ Significant bleeding risk or coagulation disorders, at Screening.
✕ Use of exclusionary medication prior to Screening/randomization as listed in the protocol.
✕ Other protocol-defined inclusion/exclusion critria may apply